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Drug repurposing strategies are being considered for the management of novel coronavirus disease 2019 (COVID-19). The janus kinase (JAK) inhibitor, baricitinib has gained considerable research interest because it can inhibit viral assembly by preventing AP-2 associated protein kinase 1 (AAK1)-mediated endocytosis.

The most important human receptor for the severe acute respiratory syndrome (SARS) S glycoprotein is the angiotensin-converting enzyme 2 (ACE2) [@bib0001]. Novel coronavirus has a similar glycoprotein that may also target this enzyme. ACE2 is predominantly found in the lower respiratory tract, particularly in the lung AT2 alveolar epithelial cells [@bib0002], which are prone to viral infections like SARS coronavirus [@bib0003]. These AT2 alveolar epithelial cells might contribute to viral reproduction and transmission through endocytosis [@bib0004]. AAK1 is a potential promoter of this endocytosis, thus enhancing viral assembly in the intracellular matrix [@bib0005]. Cyclin G-associated kinase is another regulator of this endocytosis [@bib0006].

Baricitinib is a potential option for the management of disease caused by novel coronaviruses. Baricitinib inhibits both AAK1 and cyclin G-associated kinase, thereby preventing endocytosis and reducing viral assembly. Baricitinib inhibits JAK1 and JAK2 and therefore may help manage inflammation [@bib0007]. Several studies suggested the use of baricitinib for treating COVID-19 [@bib0003],[@bib0008].

Study results indicate that baricitinib cannot be initiated in patients with an absolute neutrophil count less than 1 × 10^9^ cells/L, or in patients with an absolute lymphocyte count less than 0.5 × 10^9^ cells/L [@bib0009]. Epidemiological studies show the values of the selected patients are closer to the threshold levels at baseline ([Table 1](#tbl0001){ref-type="table"} ) [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014]. In one epidemiological study, absolute lymphocyte count in non-survivors was reported to be 0 · 6 × 10^9^ cells/L (interquartile range: 0 · 5--0 · 8 × 10^9^ cells/L) ([Table 2](#tbl0002){ref-type="table"} ) [@bib0014]. Similarly, another study carried out by Huang et al*.* reported that absolute lymphocyte count in infected patients in ICU was 0 · 4 × 10^9^ cells/L (interquartile range: 0 · 2--0 · 8 × 10^9^ cells/L) [@bib0012]. The risk of lymphocytopenia may affect the progression of COVID-19. A 26% incidence of anaemia has been reported in non-survivors of COVID-19 infection [@bib0014]. Baricitinib therapy is predicted to be associated with incidence of anaemia [@bib0015]; therefore, initiation of baricitinib therapy in patients with COVID-19 may further increase anaemia incidence [@bib0009].Table 1Published biochemical data of COVID-19 patients.Table 1ParameterReference rangeWang et al ^10^Chen et al ^11^Huang et al ^12^Ng et al ^13^Zhou et al ^14^No. of patients-991384121191Absolute neutrophil count (x10^9^ cells/L)2.0-7.43.0 (2.0-4.9)5.0 (3.3-8.1)5.0 (3.0-8.9)3.33 (3-3.91)NAAbsolute lymphocyte count (x10^9^ cells/L)1.1-3.60.8 (0.6-1.1)0.9 (0.5)0.8 (0.6-1.1)1.29 (0.7-1.65)1 · 0 (0 · 6-1 · 3)Creatine kinase (U/L)\<170102 (62- 252)85.0 (51-184)132.0 (62-219)78.0 (69-137)21 · 5 (13 · 0-72 · 4)[^1]Table 2Published biochemical data of COVID-19 patients in ICU and non-survivors.Table 2ParameterReference rangeWang et al ^10^ (n=138)Huang et al ^12^ (n=41)Zhou et al ^14^ (n=191)ICU/non-survivors-ICUICUNon-survivorsNo. of patients-361354Absolute lymphocyte count (x 10^9^ cells/L)1.1-3.60.8 (0.5-0.9)0 · 4 (0 · 2-0 · 8)0 · 6 (0 · 5-0 · 8)No. of patients (%) with lymphocytopenia-NA11 (85%)41 (76%)Creatine kinase (U/L)\<170102 (62-252)132 · 0 (82 · 0-493 · 0)39 · 0 (19 · 5-151 · 0)No. of patients (%) with elevated creatine kinase-NA6/13 (46%)11/52 (21%)^\#^[^2]

Elevated creatine kinase has been observed in patients receiving baricitinib therapy [@bib0015]. Although the median value of creatine kinase is reported to be in the normal range (\<175 U/L) in patients with COVID-19, it is greatly increased in critically ill patients and non-survivors of this disease [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014]. A total of 46% of patients with COVID-19 in ICU have been reported to have elevated creatine kinase levels [@bib0012]. In one critically ill COVID-19 patient, creatine kinase levels were as high as 493 U/L [@bib0012]. Elevated creatine kinase levels pose a risk for the initiation of baricitinib therapy.

Limited data are available on the potential effects of baricitinib in the elderly population aged at least 75 years [@bib0015]. Zhou et al. reported that mortality is higher in elderly infected patients [@bib0014]. Furthermore, studies have shown increased incidence of respiratory tract infections (16.3%) and incidence of infective diseases (29-42%). Co-infection is one of the most common threats in the management of COVID-19 [@bib0010]. There is also a risk of re-activation of latent infections. Infected patients will also be at risk of tuberculosis and hepatitis B [@bib0016]. Researchers have concluded that baricitinib therapy can reactivate varicella-zoster, herpes simplex and Epstein-Barr virus strains [@bib0017]. Zhou et al. reported that 50% of patients with COVID-19 experienced secondary infections [@bib0014].

Baricitinib may not be an ideal drug of choice for management of COVID-19. Available therapeutic options must be explored to prevent mortality in patients with this disease.
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[^1]: Values are median (interquartile range). NA - Not Available

[^2]: Values are median (interquartile range). NA - Not Available. ^\#^Data not available for 2 patients
